系统性审查的复制:它是否有利于或损害方法质量?
Céline Chapelle1, Edouard Ollier1, Paul Bonjean2
1Univ. Jean Monnet, Mines Saint- Étienne, INSERM, U1059, SAINBIOSE, CHU Saint-Étienne, Service de Pharmacologie Clinique, F-42023 Saint-Étienne, France.
许多关于直接口服抗凝剂的系统评价 (SR) 是复制品,其中五分之一是过度的. 这些复制并没有比原来的SR提高方法质量.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 证据综合和元分析
背景情况:
- 直接口服抗凝剂对于治疗急性静脉血栓塞栓症至关重要.
- 许多系统性审查 (SRs) 存在,引发了对冗余性和质量的担忧.
研究的目的:
- 评估重叠情况,并描述 SRs对静脉血栓栓塞的直接口服抗凝剂的方法质量和偏差风险.
主要方法:
- 一个全面的PubMed搜索确定了到2022年1月31日发表的SR.
- 使用系统性审查中的偏差风险 (ROBIN-E) 工具评估了偏差风险.
- 冗余性是由重叠的种群,干预措施和包括的研究来定义的.
主要成果:
- 在144个SR中,26个是原创的,87个是概念复制,31个是过度复制.
- 偏见的高风险在所有类别中普遍存在:原始的73.1%,概念的74.7%,过度复制的67.7%.
- 与原始相比,复制的SRs的方法质量没有得到改善.
结论:
- 在直接口服抗凝剂中,显著比例的SR是复制,其中很大一部分是过度的.
- 复制SRs并没有提高方法质量,这表明证据合成中的潜在效率低下.
更多相关视频
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
08:29An Open Source Technology Platform to Manufacture Hydrogel-Based 3D Culture Models in an Automated and Standardized Fashion
Published on: March 31, 2022
相关概念视频
Data Validation
Key parameters for method validation include:
Systematic Error: Methodological and Sampling Errors
Sampling errors originate from improper sampling methods or the wrong sample population. These errors can be minimized by refining the sampling strategy. Defective instruments or faulty calibrations are the sources of instrumental...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
The DNA Replication Fork
Statistical Analysis: Overview
One of the most commonly used statistical quantifiers is the mean, which is the ratio between the sum of the numerical values of all results and the...
Accuracy and Errors in Hypothesis Testing
In hypothesis testing, the probability of making a Type I error, denoted as α, is commonly set at 0.05. This significance level indicates a 5%...
